Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly

Diabetes Care

Volumn 35, Issue 7, 2012, Pages 1519-1524

  Lind, P Monica ^a   Zethelius, Björn ^a,b   Lind, Lars ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; INSULIN; MONO (2 ETHYLHEXYL)PHTHALATE; MONOETHYL PHTHALIC ACID; MONOISOBUTYL PHTHALIC ACID; MONOMETHYL PHTHALIC ACID; PHTHALIC ACID; PHTHALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENVIRONMENTAL EXPOSURE; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MODELS, BIOLOGICAL; PHTHALIC ACIDS; PREVALENCE; PROINSULIN;

EID: 84862884577     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2396     Document Type: Article

References (33)

1. Frederiksen H, Skakkebaek NE, Andersson A-M. Metabolism of phthalates in humans. Mol Nutr Food Res 2007;51:899-911 (Pubitemid 47173700)
2. Heudorf U, Mersch-Sundermann V, Angerer J. Phthalates: toxicology and exposure. Int J Hyg Environ Health 2007;210:623-634 (Pubitemid 47539285)
3. Heindel JJ, Powell CJ. Phthalate ester effects on rat Sertoli cell function in vitro: effects of phthalate side chain and age of animal. Toxicol Appl Pharmacol 1992;115:116-123
4. Koch HM, Bolt HM, Preuss R, Angerer J. New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. Arch Toxicol 2005;79:367-376 (Pubitemid 41040172)
5. Wittassek M, Angerer J. Phthalates: metabolism and exposure. Int J Androl 2008; 31:131-138
6. Koch HM, Preuss R, Angerer J. Di(2-ethylhexyl)phthalate (DEHP): human metabolism and internal exposure: an update and latest results. Int J Androl 2006;29: 155-165; discussion 181-185
7. Halden RU. Plastics and health risks. Annu Rev Public Health 2010;31:179-194
8. Högberg J, Hanberg A, Berglund M, et al. Phthalate diesters and their metabolites in human breast milk, blood or serum, and urine as biomarkers of exposure in vulnerable populations. Environ Health Perspect 2008;116:334-339 (Pubitemid 351395601)
9. Lind PM, Lind L. Circulating levels of bisphenol A and phthalates are related to carotid atherosclerosis in the elderly. Atherosclerosis 2011;218:207-213
10. Hatch EE, Nelson JW, Qureshi MM, et al. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002. Environ Health 2008;7:27
11. Bornehag CG, Sundell J, Weschler CJ, et al. The association between asthma and allergic symptoms in children and phthalates in house dust: a nested case-control study. Environ Health Perspect 2004;112: 1393-1397 (Pubitemid 39386556)
12. Martino-Andrade AJ, Chahoud I. Reproductive toxicity of phthalate esters. Mol Nutr Food Res 2010;54:148-157
13. Boberg J, Metzdorff S, Wortziger R, et al. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats. Toxicology 2008;250:75-81
14. Feige JN, Gelman L, Rossi D, et al. The endocrine disruptor monoethyl-hexylphthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem 2007;282:19152-19166 (Pubitemid 47100190)
15. Feige JN, Gerber A, Casals-Casas C, et al. The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect 2010; 118:234-241
16. Kaya T, Mohr SC, Waxman DJ, Vajda S. Computational screening of phthalate monoesters for binding to PPARgamma. Chem Res Toxicol 2006;19:999-1009 (Pubitemid 44384830)
17. Venkata NG, Robinson JA, Cabot PJ, Davis B, Monteith GR, Roberts-Thomson SJ. Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicol Lett 2006;163: 224-234
18. Lapinskas PJ, Brown S, Leesnitzer LM, et al. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. Toxicology 2005;207:149-163 (Pubitemid 39601694)
19. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci 2003;74:297-308 (Pubitemid 36958298)
20. Kim SK, Hur KY, Kim HJ, et al. The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. Eur J Endocrinol 2007;157:167-174
21. Thomas EL, Potter E, Tosi I, et al. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. Atherosclerosis 2007;195:e181-e190 (Pubitemid 47561966)
22. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56: 265-294
23. Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect 2007;115:876-882 (Pubitemid 46902242)
24. Arnlöv J, Sundström J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care 2011;34:61-65
25. Svensson K, Hernández-Ramírez RU, Burguete-García A, et al. Phthalate exposure associated with self-reported diabetes among Mexican women. Environ Res 2011;111:792-796
26. Olsén L, Lampa E, Birkholz DA, Lind L, Lind PM. Circulating levels of bisphenol A (BPA) and phthalates in an elderly population in Sweden, based on the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS). Ecotoxicol Environ Saf 2012;75:242-248
27. Davies MJ, Rayman G, Gray IP, Day JL, Hales CN. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabet Med 1993;10:313-320 (Pubitemid 23134737)
28. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997;46: 1725-1732 (Pubitemid 27456403)
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-419 (Pubitemid 15018832)
30. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med Res 1995;4:187-196
31. Calafat AM, McKee RH. Integrating biomonitoring exposure data into the risk assessment process: phthalates [diethyl phthalate and di(2-ethylhexyl) phthalate] as a case study. Environ Health Perspect 2006;114:1783-1789 (Pubitemid 44718287)
32. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in themodulation of insulin secretion. Am J Physiol Endocrinol Metab 2004;286: E560-E567 (Pubitemid 38374953)
33. Moon JH, Kim HJ, Kim SK, et al. Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. Metabolism 2011;60:165-172